{"ok":true,"api":{"name":"SAIMSARA Evidence Object Discovery API","version":"v1"},"mode":"doc_key","editorial_verification":{"status":"human_reviewed","trust_label":"machine_generated_human_reviewed","method":"World ID proof-of-human editorial account","scope":["clinical_integrity","reference_quality","scientific_coherence"],"verification_note":"This Evidence Object is machine-generated and human-reviewed. World ID is used to verify that editorial oversight was submitted by a unique human account.","does_not_mean":"World ID verifies proof-of-human editorial oversight; it does not independently certify the scientific truth of every claim."},"object":{"object_type":"saimsara_evidence_object_metadata","doc_key":"vascular::SEMAGLUTIDE_PM","issue_slug":"vascular","doc_id":"SEMAGLUTIDE_PM","title":"Semaglutide","doi":"10.62487/saimsara45190890","doi_url":"https://doi.org/10.62487/saimsara45190890","version":"2026-04-16","source_name":"PubMed","article_url":"https://saimsara.com/sessions/semaglutide-20260106-110453-45190890/","image_url":"","topic_tags":"Type 2 diabetes mellitus,Obesity management,GLP-1 receptor agonists,Chronic kidney disease,Cardiovascular outcomes,Body composition,Medication adherence,Quality of life,Pharmacoeconomics,Adverse effects","keywords":["Type 2 diabetes mellitus","Obesity management","GLP-1 receptor agonists","Chronic kidney disease","Cardiovascular outcomes","Body composition","Medication adherence","Quality of life","Pharmacoeconomics","Adverse effects"],"metrics":{"included_all":3680,"included_original":1462,"reference_index":255,"total_participants":15902477},"discover_url":"https://saimsara.com/api/v1/discover.php?doc_key=vascular%3A%3ASEMAGLUTIDE_PM","paid_evidence_url":"https://saimsara.com/api/v1/evidence.php?doc_key=vascular%3A%3ASEMAGLUTIDE_PM","price":{"amount":"5.00","currency":"USD","units":5,"unit_amount":"1.00"},"payment_methods":["api_key","stripe_checkout","object_grant","x402"],"text_length":26266,"preview":"Results Study-Level Evidence Map: semaglutide → Outcome Favorable ΣN=6048972 (38%) Unfavorable ΣN=2479028 (16%) Neutral ΣN=7374577 (46%) Key finding aligned to the query: Semaglutide demonstrates robust, dose-dependent reductions in body weight and glycated hemoglobin (HbA1c) across diverse clinical populations, with weight loss ranging from a median of -10.3% in obesity-focused cohorts to -20.4% in high-dose cagrilintide-semaglutide combinations. These metabolic improvements are consistently associated with significant reductions in major adverse cardiovascular events (MACE), with hazard ratios (HR) ranging from 0.74 to 0.86 in high-risk populations. Furthermore, semaglutide provides substa…","trust_label":"machine_generated_human_reviewed","editorial_verification":{"status":"human_reviewed","trust_label":"machine_generated_human_reviewed","method":"World ID proof-of-human editorial account","scope":["clinical_integrity","reference_quality","scientific_coherence"],"verification_note":"This Evidence Object is machine-generated and human-reviewed. World ID is used to verify that editorial oversight was submitted by a unique human account.","does_not_mean":"World ID verifies proof-of-human editorial oversight; it does not independently certify the scientific truth of every claim."},"checkout":{"method":"POST","url":"https://saimsara.com/create_checkout_session.php","content_type":"application/x-www-form-urlencoded","params":{"plan":"evidence_object","doc_key":"vascular::SEMAGLUTIDE_PM"},"optional_params":{"customer_email":"user@example.com"},"price":{"amount":"5.00","currency":"USD","units":5,"unit_amount":"1.00"},"curl_example":"curl -X POST https://saimsara.com/create_checkout_session.php -d \"plan=evidence_object\" -d \"doc_key=vascular::SEMAGLUTIDE_PM\" -d \"customer_email=user@example.com\""},"access_after_payment":{"header":"X-SAIMSARA-Payment-Proof","endpoint":"https://saimsara.com/api/v1/evidence.php?doc_key=vascular%3A%3ASEMAGLUTIDE_PM","curl_example":"curl -H \"X-SAIMSARA-Payment-Proof: YOUR_PAYMENT_PROOF_TOKEN\" \"https://saimsara.com/api/v1/evidence.php?doc_key=vascular%3A%3ASEMAGLUTIDE_PM\""}}}